

Amendments to the Claims

Please cancel claims 1-22.

23. (Original) A method for treating a degenerative neurological disorder involving a potassium channel formed by the coexpression of KCNQ2 and KCNQ3 comprising administering to a subject ~~host~~ in need of such treatment a therapeutically effective amount of a compound, ~~identified by the screening assay of Claim 1~~ or a pharmaceutically acceptable salt or prodrug form thereof, identified by:

- (a) contacting a compound with a transfected cell that stably coexpresses KCNQ2 and KCNQ3 polypeptides, wherein the KCNQ2 and the KCNQ3 form a potassium channel; and
- (b) measuring the activity of the potassium channel.

24. (Original) A method for treating epilepsy involving a potassium channel formed by the coexpression of KCNQ2 and KCNQ3 comprising administering to a subject ~~host~~ in need of such treatment a therapeutically effective amount of a compound, ~~identified by the screening assay of Claim 1~~ or a pharmaceutically acceptable salt or prodrug form thereof, identified by:

- (a) contacting a compound with a transfected cell that stably coexpresses KCNQ2 and KCNQ3 polypeptides, wherein the KCNQ2 and the KCNQ3 form a potassium channel; and
- (b) measuring the activity of the potassium channel.